


IFW



INFORMATION DISCLOSURE STATEMENT

Applicant : Tamm et al.  
App. No. : 10/665,975  
Filed : September 18, 2003  
For : USE OF HEPATITIS B X-INTERACTING  
PROTEIN (HBXIP) IN MODULATION OF  
APOPTOSIS  
Examiner : Unknown  
Group Art Unit : 1648

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 31 references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

August 26, 2004

By:

Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580



PATENT

Case Docket No. BURNHAM.005A

Date: August 26, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Tamm et al.  
Appl. No. : 10/665,975  
Filed : September 18, 2003  
For : USE OF HEPATITIS B X-  
INTERACTING PROTEIN  
(HBXIP) IN MODULATION OF  
APOPTOSIS  
Examiner : Unknown  
Group Art Unit : 1648

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 26, 2004

(Date)

Marilyn L. Gordey, Reg. No. 52,950

TRANSMITTAL LETTER


Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with thirty-one (31) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Marilyn L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
BURNHAM.005AAPPLICATION NO.  
10/665,975INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Tamm et al.FILING DATE  
September 18, 2003GROUP  
1648

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER  
INITIAL


## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

1.	Ambrosini, G. et al. "A novel anti-apoptosis gene, <i>survivin</i> , expressed in cancer and lymphoma." <i>Nature Med</i> 3:917-921 (1997).
2.	Banks, D.P. et al. "Survivin does not inhibit caspase-3 activity." <i>Blood</i> 96:4002-4003 (2000).
3.	Bratton, S.B. et al. "Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes." <i>EMBO J</i> 20:998-1009 (2001).
4.	Cryns, V. et al. "Proteases to die for." <i>Genes Dev</i> 12:1551-1570 (1998).
5.	Deveraux, Q.L. et al. "IAP family proteins: Suppressors of apoptosis." <i>Genes Dev</i> 13:239-252 (1999).
6.	Deveraux, Q.L. et al. "X-linked IAP is a direct inhibitor of cell death proteases." <i>Nature</i> 388:300-304 (1997).
7.	Gottlob, K. et al. "The Hepatitis B virus HBx protein inhibits caspase 3 activity." <i>J Biol Chem</i> 273:33347-33353 (1998).
8.	Grossman, D. et al. "Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53." <i>J Clin. Invest</i> 108:991-999 (2001).
9.	Kim, C.M. et al. "HBx gene of hepatitis B virus induces liver cancer in transgenic mice." <i>Nature</i> 351:317-320 (1991).
10.	Li, F. et al. "Control of apoptosis and mitotic spindle checkpoint by survivin." <i>Nature</i> 396:580-584 (1998).
11.	Li, P. et al. "Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade." <i>Cell</i> 91:479-489 (1997).
12.	Lok, A.S. "Hepatitis B infection: Pathogenesis and management." <i>J Hepatol</i> 32:89-97 (2000).
13.	Marusawa, H. et al. "HBXIP functions as a cofactor of survivin in apoptosis suppression" <i>The EMBO J.</i> 22:2729-2740 (2003)
14.	Marusawa, H. et al. "Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen." <i>Hepatology</i> 31:488-495 (2000).
15.	Matsuzawa, S. et al. "Siah-1, SIP, and Ebi collaborate in a novel pathway for -catenin degradation linked to p53 responses." <i>Mol Cell</i> 7:915-926 (2001).
16.	Melegari, M. et al. "Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication." <i>J Virol</i> 72:1737-1743 (1998).

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

 FORM PTO-7449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BURNHAM.005A	APPLICATION NO. 10/665,975
	APPLICANT Tamm et al.	
	FILING DATE September 18, 2003	GROUP 1648

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
17.	Murakami, S. "Hepatitis B virus X protein: A multifunctional viral regulator." <i>J Gastroenterol</i> 36:651-660 (2001).
18.	O'Connor, D.S. et al. "Regulation of apoptosis at cell division by p34 <sup>cdc2</sup> phosphorylation of survivin." <i>PNAS USA</i> 97:13103-13107 (2000).
19.	Reed, J.C. et al. "BIRing chromosomes through cell division - and survivin the experience." <i>Cell</i> 102: 545-548 (2000).
20.	Reed, J.C. "The survivin saga goes in vivo." <i>J Clin Invest</i> 108:965-969 (2001).
21.	Riedl, S.J. et al. "Structural basis for the inhibition of caspase-3 by XIAP." <i>Cell</i> 104:791-800 (2001).
22.	Salvesen, G.S. "Caspases: opening the boxes and interpreting the arrows." <i>Cell Death Differ</i> 9:3-5 (2002).
23.	Shin, S. et al. "An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7." <i>Biochem</i> 40: 1117-1123 (2001).
24.	Stennicke, H.R. et al. "Caspase-9 can be activated without proteolytic processing." <i>J Biol Chem</i> 274:8359-8362 (1999).
25.	Sun, C. et al. "NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP." <i>Nature</i> 401:818-822 (1999).
26.	Tamm, I. et al. "IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs." <i>Cancer Res</i> 58:5315-5320 (1998).
27.	Velculescu, V.E. et al. "Analysis of human transcriptomes." <i>Nature Gen</i> 23:387-388 (1999).
28.	Verdecia, M.A. et al. "Structure of the Human anti-apoptotic protein survivin reveals a dimeric arrangement." <i>Nature Struct Biol</i> 7:602-608 (2000).
29.	Yang, J. et al. "Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked." <i>Science</i> 275: 1129-1132 (1997).
30.	Zhou, Q. et al. "Target protease specificity of the viral serpin CrmA: analysis of five caspases." <i>J Biol Chem</i> 272: 7797-7800 (1997)
31.	Zou, H. et al. "An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9." <i>J Biol Chem</i> 274:11549-11556 (1999).

O:\DOCS\MXG\MXG-5079.DOC:vr  
042904

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	